Skip to main content

Table 4 Association of Direct oral anticoagulant use (vs. warfarin) after atrial fibrillation diagnosis with cardiovascular events, by sex, among elderly participants in the MarketScan database (2007–2015)

From: Sex differences in treatment strategy and adverse outcomes among patients 75 and older with atrial fibrillation in the MarketScan database

Outcome

Men

Women

p value for multiplicative interaction

ICR

Model 1

Model 2††

Model 1

Model 2††

Warfarin

DOAC

Warfarin

DOAC

Warfarin

DOAC

Warfarin

DOAC

Heart failure

 Events/N

4799/54,192

355/8461

4799/54,192

355/8461

4149/49,845

312/8130

4149/49,845

312/8130

0.89

0.02

 HR (95% CI)

1 (ref.)

0.81 (0.73, 0.91)

1 (ref.)

0.94 (0.84, 1.05)

1 (ref.)

0.82 (0.73, 0.92)

1 (ref.)

0.93 (0.83, 1.04)

  

Stroke

 Events/N

1328/54,411

93/8487

1328/54,411

93/8487

1766/50,031

140/8155

1766/50,031

140/8155

0.3

0.119

 HR (95% CI)

1 (ref.)

0.85 (0.69, 1.05)

1 (ref.)

0.89 (0.72, 1.10)

1 (ref.)

1.00 (0.84, 1.19)

1 (ref.)

1.01 (0.86, 1.22)

  

Major bleeding

 Events/N

3390/54,315

286/8481

3390/54,315

286/8481

3066/49,981

273/8144

3066/49,981

273/8144

0.56

0.063

 HR (95% CI)

1 (ref.)

0.99 (0.88, 1.12)

1 (ref.)

1.01 (0.89, 1.14)

1 (ref.)

0.99 (0.87, 1.12)

1 (ref.)

1.03 (0.90, 1.16)

  
  1. HR hazard ratio, CI confidence interval, ICR interaction contrast ratio
  2. Bolded results are statistically significant at p value of 0.05
  3. Model 1 adjusts for age
  4. ††Model 2 adjusts for age plus heart failure, hypertension, diabetes mellitus, stroke, myocardial infarction, peripheral arterial disease, chronic kidney disease, gastrointestinal bleed, liver disease, hyperlipidemia, chronic obstructive pulmonary disease, depression, dementia, intracranial bleeding, other forms of bleeding, alcohol abuse, use of lipid lowering medication, beta blockers, calcium channel blockers, angiotensin receptor blocker, angiotensin converting enzyme inhibitor, diuretics, gastrointestinal drugs, cardiac drugs, potassium supplements, anti-diabetics, anti-platelet drugs, thiazide diuretics, anti-arrhythmics, insulin, sulphonylureas, other diuretics, statins and digoxin